RNA in disease

Projektinformationen

RiboMed

ID Finanzhilfevereinbarung: 857119

DOI

10.3030/857119

Projekt abgeschlossen

EK-Unterschriftsdatum 9 Juli 2019

Startdatum 1 September 2019

Enddatum 28 Februar 2023

Finanziert unter

• Twinning of research institutions

Gesamtkosten

€ 799 750,00

EU-Beitrag

€ 799 750,00

Koordiniert durch

FUNDACAO GIMM - GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE
Portugal

Periodic Reporting for period 2 - RiboMed (RNA in disease)

Berichtszeitraum: 2020-12-01 bis 2023-02-28

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

The Instituto de Medicina Molecular João Lobo Antunes (iMM) ranks among the top research institutions in Portugal. However, the institute faces a number of constraints related to reduced availability of national research funding and access to cutting-edge resources and scientific infrastructure. RiboMed was set on the strategic vision of iMM to boost its community of RNA researchers, placing the institute in Lisbon within the core of European laboratories that are producing frontier research on how RNA shapes the complexity of human disease.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

RiboMed strengthened existing interactions and promoted the creation of new collaborations between iMM groups and researchers at the University of Oxford, MDC Berlin and the Weizmann Institute, mainly through short-term staff exchanges, on-site training and expert visits. Advances generated by these collaborations were published in seven scientific articles and two pre-prints. RiboMed further contributed to nurture a community of self-challenging and ambitious students and early-stage researchers at iMM through ensuring external expert mentoring and facilitating attendance of international conferences. Two Summer Schools were organized at iMM, mingling early-stage researchers from the four RiboMed partner institutions. Additionally, RiboMed raised the international visibility of iMM through a seminar series program, on-site workshops and an international conference on RNA and disease. Finally, RiboMed consolidated the innovation and entrepreneurship ecosystem at iMM through translation of basic findings into potential novel RNA biomarkers, RNA-based diagnostic assays and RNA therapeutic targets.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Networking promoted by RiboMed partners resulted in four new projects approved for funding at iMM. Moreover, RiboMed contributed to increase institutional awareness for the RNA field. Indeed, iMM Group Leaders that were not initially involved with RiboMed have made important discoveries related to RNA, and the Board of Directors approved the recruitment of a new Group Leader who will work at iMM on RNA binding proteins.

Logo